Literature DB >> 16843878

Anti-Saccharomyces cerevisiae antibodies are associated with the development of postoperative fistulas following ileal pouch-anal anastomosis.

Kleanthis G Dendrinos1, James M Becker, Arthur F Stucchi, Lawrence J Saubermann, Wayne LaMorte, Francis A Farraye.   

Abstract

Although serologic testing for perinuclear antineutrophil cytoplasmic antibodies (pANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA) is reportedly useful in distinguishing ulcerative colitis (UC) from Crohn's disease (CD), there are few and conflicting reports assessing their utility in predicting postoperative complications after ileal pouch-anal anastomosis (IPAA). We examined the associations between postoperative complications such as pouchitis or fistulas and pANCA and ASCA antibodies in a group of patients who underwent IPAA for UC. We conducted a retrospective chart review of 34 patients initially diagnosed with UC (four of these patients had a diagnosis of indeterminate colitis) who underwent IPAA by a single surgeon, and who had pANCA and ASCA antibody levels measured during their clinical course. Study patients were assigned to four groups based on the pattern of antibody reactivity: pANCA+/ASCA- (16 patients), pANCA-/ASCA+ (nine patients), pANCA+/ASCA+ (five patients), and pANCA-/ASCA- (four patients). The median length of follow-up was 16 months (3-144 months). None of the patients (0 of 16) who were pANCA+/ASCA- had their preoperative diagnosis of UC changed after a median follow-up of 14 months (3-118 months). Of the nine patients with a preoperative diagnosis of UC who were pANCA-/ASCA+, four patients (44%) had their diagnosis changed postoperatively to CD based on clinical findings, with a median follow-up: 15 months (5-98 months). Of 16 patients who underwent IPAA and who were pANCA+/ASCA-, 15 of 16 (93.75%), were free of fistulas postoperatively, with a median follow-up of 14 months (3-118 months). Of nine patients with a preoperative diagnosis of UC who underwent IPAA and who were pANCA-/ASCA+, four of nine (44%; p = 0.04) developed fistulas postoperatively, with a median length of follow-up of 55 months (15-67 months). No relationship between serologic profiles or antibody titer levels and the development of pouchitis was identified. In a cohort of patients undergoing IPAA for UC, serologic profiles may be useful in identifying patients at risk of postoperative fistula formation. Patients who were pANCA-/ASCA+ were at increased risk for the development of fistulas postoperatively compared to patients who were pANCA+/ASCA-, and were also more likely to have their diagnosis changed postoperatively to CD. A larger study is needed to validate these observations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16843878     DOI: 10.1016/j.gassur.2006.02.004

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  23 in total

1.  [p-ANCA and ASCA antibodies in the differential diagnosis between ulcerative rectocolitis and Crohn's disease].

Authors:  Pierenrico Lecis; Bastianello Germanà; Nunziato Papa; Gianni Bertiato; Claudio Doglioni; Ermenegildo Galliani; Franco Costan Biedo
Journal:  Recenti Prog Med       Date:  2002-05

Review 2.  Proctocolectomy with ileoanal anastomosis.

Authors:  James M Becker; Arthur F Stucchi
Journal:  J Gastrointest Surg       Date:  2004 May-Jun       Impact factor: 3.452

3.  Antineutrophil cytoplasmic antibody subtypes in children and adolescents after ileal pouch-anal anastomosis for ulcerative colitis.

Authors:  A G Kaditis; J Perrault; W J Sandborn; C J Landers; A R Zinsmeister; S R Targan
Journal:  J Pediatr Gastroenterol Nutr       Date:  1998-04       Impact factor: 2.839

4.  Fate of the pouch in 151 pediatric patients after ileal pouch anal anastomosis.

Authors:  Frederick Alexander; Samra Sarigol; John DiFiore; Anthony Stallion; Kathy Cotman; Holly Clark; Barb Lydzinski; Victor Fazio
Journal:  J Pediatr Surg       Date:  2003-01       Impact factor: 2.545

5.  Outcome of ileal pouch after secondary diagnosis of Crohn's disease.

Authors:  V Peyrègne; Y Francois; F N Gilly; J L Descos; B Flourie; J Vignal
Journal:  Int J Colorectal Dis       Date:  2000-02       Impact factor: 2.571

6.  Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease.

Authors:  M C Dubinsky; J J Ofman; M Urman; S R Targan; E G Seidman
Journal:  Am J Gastroenterol       Date:  2001-03       Impact factor: 10.864

7.  Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease.

Authors:  D G Forcione; M J Rosen; J B Kisiel; B E Sands
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

8.  Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations.

Authors:  L J Walker; M C Aldhous; H E Drummond; B R K Smith; E R Nimmo; I D R Arnott; J Satsangi
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

Review 9.  Advances in clinical laboratory tests for inflammatory bowel disease.

Authors:  Robert M Nakamura; Mariko Matsutani; Mary Barry
Journal:  Clin Chim Acta       Date:  2003-09       Impact factor: 3.786

10.  Cumulative failure rate of ileal pouch-anal anastomosis and quality of life after failure.

Authors:  Anna Lepistö; Pekka Luukkonen; Heikki J Järvinen
Journal:  Dis Colon Rectum       Date:  2002-10       Impact factor: 4.585

View more
  14 in total

1.  Current and future role of serogenomics in ulcerative colitis.

Authors:  Mark H Flasar; Raymond K Cross; David B Doman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

2.  Utility of fecal and serum anti-Saccharomyces cerevisiae antibodies in the diagnosis of Crohn's disease-like condition of the pouch.

Authors:  Linda Y Tang; Hui Cai; Udayakumar Navaneethan; James H Boone; Sarah J Rhodes; Lauren Moore; Hyunjin Rho; Carol de La Motte; Elaine Queener; Bo Shen
Journal:  Int J Colorectal Dis       Date:  2012-03-20       Impact factor: 2.571

3.  Infliximab to Treat Refractory Inflammation After Pelvic Pouch Surgery for Ulcerative Colitis.

Authors:  Orlaith B Kelly; Morgan Rosenberg; Andrea D Tyler; Joanne M Stempak; A Hillary Steinhart; Zane Cohen; Gordon R Greenberg; Mark S Silverberg
Journal:  J Crohns Colitis       Date:  2015-12-30       Impact factor: 9.071

4.  ASCA IgG and CBir antibodies are associated with the development of Crohn's disease and fistulae following ileal pouch-anal anastomosis.

Authors:  Jennifer A Coukos; Lauren A Howard; Janice M Weinberg; James M Becker; Arthur F Stucchi; Francis A Farraye
Journal:  Dig Dis Sci       Date:  2012-02-07       Impact factor: 3.199

Review 5.  Indeterminate colitis.

Authors:  P J Mitchell; M Y Rabau; N Y Haboubi
Journal:  Tech Coloproctol       Date:  2007-05-25       Impact factor: 3.781

Review 6.  Advances in epidemiology and diagnosis of inflammatory bowel diseases.

Authors:  Sobia Ali; Cyrus P Tamboli
Journal:  Curr Gastroenterol Rep       Date:  2008-12

7.  Is pyloric gland metaplasia in ileal pouch biopsies a marker for Crohn's disease?

Authors:  Shuchi Agarwal; Arthur F Stucchi; Kleanthis Dendrinos; Sandra Cerda; Michael J O'Brien; James M Becker; Timothy Heeren; Francis A Farraye
Journal:  Dig Dis Sci       Date:  2013-03-30       Impact factor: 3.199

Review 8.  The use of prognostic factors in inflammatory bowel diseases.

Authors:  Thomas Billiet; Marc Ferrante; Gert Van Assche
Journal:  Curr Gastroenterol Rep       Date:  2014-11

9.  Serologic markers associated with development of Crohn's disease after ileal pouch anal anastomosis for ulcerative colitis.

Authors:  Brindusa Truta; Dan X Li; Uma Mahadevan; Elena R Fisher; Yunn-Y Chen; Kim Grace; Fernando Velayos; Jonathan P Terdiman
Journal:  Dig Dis Sci       Date:  2013-10-04       Impact factor: 3.199

10.  Identification of novel serological biomarkers for inflammatory bowel disease using Escherichia coli proteome chip.

Authors:  Chien-Sheng Chen; Sean Sullivan; Troy Anderson; Aik Choon Tan; Philip J Alex; Steven R Brant; Carmen Cuffari; Theodore M Bayless; Monica V Talor; C Lynne Burek; Huan Wang; Richard Li; Lisa Wu Datta; Yuqiong Wu; Raimond L Winslow; Heng Zhu; Xuhang Li
Journal:  Mol Cell Proteomics       Date:  2009-04-07       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.